Infliximab and Biosimilar market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Infliximab and Biosimilar market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Infliximab and Biosimilar market is segmented into
Infliximab
Infliximab-dyyb
Infliximab-abda
Segment by Application, the Infliximab and Biosimilar market is segmented into
Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Plaque Psoriasis
Regional and Country-level Analysis
The Infliximab and Biosimilar market is analysed and market size information is provided by regions (countries).
The key regions covered in the Infliximab and Biosimilar market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Infliximab and Biosimilar Market Share Analysis
Infliximab and Biosimilar market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Infliximab and Biosimilar business, the date to enter into the Infliximab and Biosimilar market, Infliximab and Biosimilar product introduction, recent developments, etc.
The major vendors covered:
Janssen Biotech
Merck and Co.
Pfizer
...
1 Study Coverage
1.1 Infliximab and Biosimilar Product Introduction
1.2 Market Segments
1.3 Key Infliximab and Biosimilar Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Infliximab and Biosimilar Market Size Growth Rate by Type
1.4.2 Infliximab
1.4.3 Infliximab-dyyb
1.4.4 Infliximab-abda
1.5 Market by Application
1.5.1 Global Infliximab and Biosimilar Market Size Growth Rate by Application
1.5.2 Crohn's Disease
1.5.3 Pediatric Crohn's Disease
1.5.4 Ulcerative Colitis
1.5.5 Rheumatoid Arthritis
1.5.6 Ankylosing Spondylitis
1.5.7 Psoriatic Arthritis
1.5.8 Plaque Psoriasis
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Infliximab and Biosimilar Market Size, Estimates and Forecasts
2.1.1 Global Infliximab and Biosimilar Revenue 2015-2026
2.1.2 Global Infliximab and Biosimilar Sales 2015-2026
2.2 Global Infliximab and Biosimilar, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.3 Infliximab and Biosimilar Historical Market Size by Region (2015-2020)
2.3.1 Global Infliximab and Biosimilar Retrospective Market Scenario in Sales by Region: 2015-2020
2.3.2 Global Infliximab and Biosimilar Retrospective Market Scenario in Revenue by Region: 2015-2020
2.4 Infliximab and Biosimilar Market Estimates and Projections by Region (2021-2026)
2.4.1 Global Infliximab and Biosimilar Sales Forecast by Region (2021-2026)
2.4.2 Global Infliximab and Biosimilar Revenue Forecast by Region (2021-2026)
3 Global Infliximab and Biosimilar Competitor Landscape by Players
3.1 Global Top Infliximab and Biosimilar Sales by Manufacturers
3.1.1 Global Infliximab and Biosimilar Sales by Manufacturers (2015-2020)
3.1.2 Global Infliximab and Biosimilar Sales Market Share by Manufacturers (2015-2020)
3.2 Global Infliximab and Biosimilar Manufacturers by Revenue
3.2.1 Global Infliximab and Biosimilar Revenue by Manufacturers (2015-2020)
3.2.2 Global Infliximab and Biosimilar Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Infliximab and Biosimilar Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Infliximab and Biosimilar Revenue in 2019
3.2.5 Global Infliximab and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Infliximab and Biosimilar Price by Manufacturers
3.4 Global Infliximab and Biosimilar Manufacturing Base Distribution, Product Types
3.4.1 Infliximab and Biosimilar Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Infliximab and Biosimilar Product Type
3.4.3 Date of International Manufacturers Enter into Infliximab and Biosimilar Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Infliximab and Biosimilar Market Size by Type (2015-2020)
4.1.1 Global Infliximab and Biosimilar Sales by Type (2015-2020)
4.1.2 Global Infliximab and Biosimilar Revenue by Type (2015-2020)
4.1.3 Infliximab and Biosimilar Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Infliximab and Biosimilar Market Size Forecast by Type (2021-2026)
4.2.1 Global Infliximab and Biosimilar Sales Forecast by Type (2021-2026)
4.2.2 Global Infliximab and Biosimilar Revenue Forecast by Type (2021-2026)
4.2.3 Infliximab and Biosimilar Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Infliximab and Biosimilar Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Infliximab and Biosimilar Market Size by Application (2015-2020)
5.1.1 Global Infliximab and Biosimilar Sales by Application (2015-2020)
5.1.2 Global Infliximab and Biosimilar Revenue by Application (2015-2020)
5.1.3 Infliximab and Biosimilar Price by Application (2015-2020)
5.2 Infliximab and Biosimilar Market Size Forecast by Application (2021-2026)
5.2.1 Global Infliximab and Biosimilar Sales Forecast by Application (2021-2026)
5.2.2 Global Infliximab and Biosimilar Revenue Forecast by Application (2021-2026)
5.2.3 Global Infliximab and Biosimilar Price Forecast by Application (2021-2026)
6 China by Players, Type and Application
6.1 China Infliximab and Biosimilar Market Size YoY Growth 2015-2026
6.1.1 China Infliximab and Biosimilar Sales YoY Growth 2015-2026
6.1.2 China Infliximab and Biosimilar Revenue YoY Growth 2015-2026
6.1.3 China Infliximab and Biosimilar Market Share in Global Market 2015-2026
6.2 China Infliximab and Biosimilar Market Size by Players (International and Local Players)
6.2.1 China Top Infliximab and Biosimilar Players by Sales (2015-2020)
6.2.2 China Top Infliximab and Biosimilar Players by Revenue (2015-2020)
6.3 China Infliximab and Biosimilar Historic Market Review by Type (2015-2020)
6.3.1 China Infliximab and Biosimilar Sales Market Share by Type (2015-2020)
6.3.2 China Infliximab and Biosimilar Revenue Market Share by Type (2015-2020)
6.3.3 China Infliximab and Biosimilar Price by Type (2015-2020)
6.4 China Infliximab and Biosimilar Market Estimates and Forecasts by Type (2021-2026)
6.4.1 China Infliximab and Biosimilar Sales Forecast by Type (2021-2026)
6.4.2 China Infliximab and Biosimilar Revenue Forecast by Type (2021-2026)
6.4.3 China Infliximab and Biosimilar Price Forecast by Type (2021-2026)
6.5 China Infliximab and Biosimilar Historic Market Review by Application (2015-2020)
6.5.1 China Infliximab and Biosimilar Sales Market Share by Application (2015-2020)
6.5.2 China Infliximab and Biosimilar Revenue Market Share by Application (2015-2020)
6.5.3 China Infliximab and Biosimilar Price by Application (2015-2020)
6.6 China Infliximab and Biosimilar Market Estimates and Forecasts by Application (2021-2026)
6.6.1 China Infliximab and Biosimilar Sales Forecast by Application (2021-2026)
6.6.2 China Infliximab and Biosimilar Revenue Forecast by Application (2021-2026)
6.6.3 China Infliximab and Biosimilar Price Forecast by Application (2021-2026)
7 North America
7.1 North America Infliximab and Biosimilar Market Size YoY Growth 2015-2026
7.2 North America Infliximab and Biosimilar Market Facts & Figures by Country
7.2.1 North America Infliximab and Biosimilar Sales by Country (2015-2020)
7.2.2 North America Infliximab and Biosimilar Revenue by Country (2015-2020)
7.2.3 U.S.
7.2.4 Canada
8 Europe
8.1 Europe Infliximab and Biosimilar Market Size YoY Growth 2015-2026
8.2 Europe Infliximab and Biosimilar Market Facts & Figures by Country
8.2.1 Europe Infliximab and Biosimilar Sales by Country
8.2.2 Europe Infliximab and Biosimilar Revenue by Country
8.2.3 Germany
8.2.4 France
8.2.5 U.K.
8.2.6 Italy
8.2.7 Russia
9 Asia Pacific
9.1 Asia Pacific Infliximab and Biosimilar Market Size YoY Growth 2015-2026
9.2 Asia Pacific Infliximab and Biosimilar Market Facts & Figures by Country
9.2.1 Asia Pacific Infliximab and Biosimilar Sales by Region (2015-2020)
9.2.2 Asia Pacific Infliximab and Biosimilar Revenue by Region
9.2.3 China
9.2.4 Japan
9.2.5 South Korea
9.2.6 India
9.2.7 Australia
9.2.8 Taiwan
9.2.9 Indonesia
9.2.10 Thailand
9.2.11 Malaysia
9.2.12 Philippines
9.2.13 Vietnam
10 Latin America
10.1 Latin America Infliximab and Biosimilar Market Size YoY Growth 2015-2026
10.2 Latin America Infliximab and Biosimilar Market Facts & Figures by Country
10.2.1 Latin America Infliximab and Biosimilar Sales by Country
10.2.2 Latin America Infliximab and Biosimilar Revenue by Country
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Infliximab and Biosimilar Market Size YoY Growth 2015-2026
11.2 Middle East and Africa Infliximab and Biosimilar Market Facts & Figures by Country
11.2.1 Middle East and Africa Infliximab and Biosimilar Sales by Country
11.2.2 Middle East and Africa Infliximab and Biosimilar Revenue by Country
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 Janssen Biotech
12.1.1 Janssen Biotech Corporation Information
12.1.2 Janssen Biotech Description and Business Overview
12.1.3 Janssen Biotech Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Janssen Biotech Infliximab and Biosimilar Products Offered
12.1.5 Janssen Biotech Recent Development
12.2 Merck and Co.
12.2.1 Merck and Co. Corporation Information
12.2.2 Merck and Co. Description and Business Overview
12.2.3 Merck and Co. Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Merck and Co. Infliximab and Biosimilar Products Offered
12.2.5 Merck and Co. Recent Development
12.3 Pfizer
12.3.1 Pfizer Corporation Information
12.3.2 Pfizer Description and Business Overview
12.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Pfizer Infliximab and Biosimilar Products Offered
12.3.5 Pfizer Recent Development
12.11 Janssen Biotech
12.11.1 Janssen Biotech Corporation Information
12.11.2 Janssen Biotech Description and Business Overview
12.11.3 Janssen Biotech Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Janssen Biotech Infliximab and Biosimilar Products Offered
12.11.5 Janssen Biotech Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Infliximab and Biosimilar Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Infliximab and Biosimilar Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Janssen Biotech
Merck and Co.
Pfizer
*If Applicable.